母亲呼吸道合胞病毒疫苗接种与分娩间隔较长可提高胎盘抗体转移效率
前瞻性队列研究纳入124名孕期接种呼吸道合胞病毒疫苗者,发现接种后至少5周分娩者脐带与母体抗体转移比显著高于接种后2-4周分娩者;疫苗诱导的母体及脐带抗RSV F抗体水平显著高于自然感染。
要点
- 接种后至少5周分娩者脐带与母体抗体转移比显著高于接种后2-4周分娩者。
- 疫苗诱导的母体及脐带抗RSV F抗体水平显著高于自然感染。
- 在获批的32至36周窗口内较早接种(至少分娩前5周)可获得最高经胎盘抗体转移。
核心结论
- 在获批的32至36周窗口内较早接种疫苗(至少分娩前5周)可使母体抗体经胎盘转移至新生儿达到最高水平。
研究设计与样本
- 前瞻性队列研究,于2023年9月20日至2024年3月21日在2个学术医疗中心开展,纳入124名孕期接种呼吸道合胞病毒疫苗者。
主要发现
- 疫苗诱导的母体抗RSV F抗体水平为5.72 log10平均荧光强度,自然感染为4.82 log10平均荧光强度,P<.0001。
- 疫苗诱导的脐带抗RSV F抗体水平为5.81 log10平均荧光强度,自然感染为5.03 log10平均荧光强度,P<.0001。
- 分娩前2至3周接种者脐带与母体转移比显著低于分娩前超过5周接种者,P=.03。
- 分娩前3至4周接种者脐带与母体转移比显著低于分娩前超过5周接种者,P=.007。
- 分娩前2至3周接种者转移比显著低于妊娠30周前接种百日咳疫苗者,P=.008;分娩前3至4周接种者P=.03。
临床怎么用
- 研究结果可用于指导孕期疫苗接种时机的咨询。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Respiratory syncytial virus is associated with significant neonatal and infant morbidity and mortality. Maternal bivalent respiratory syncytial virus prefusion F respiratory syncytial virus vaccination to protect neonates and infants was approved in September 2023 for administration between 32+0 and 36+6 weeks to protect neonates and infants. This approved timeframe is narrower than the 24 to 36 week window evaluated in the clinical trial, due to the possible association between preterm birth and vaccine administration. Currently, data are lacking on how maternal vaccine timing within the approved window affects the transfer of antibodies from mother to fetus, critical information that could influence clinical practice. OBJECTIVE: We sought to examine how gestational age at vaccination and time elapsed from maternal respiratory syncytial virus vaccination to delivery impacted transfer of maternal antibodies measured in the umbilical cord at delivery and in peripheral blood of 2-month infants. We also examined differences in maternal and cord respiratory syncytial virus antibody levels achieved by vaccination vs natural RSV infection. STUDY DESIGN: A prospective cohort study was conducted at 2 academic medical centers between September 20, 2023 and March 21, 2024, enrolling 124 individuals who received the respiratory syncytial virus vaccine during pregnancy. Infant capillary blood was collected at 2 months of age from 29 of the infants. Maternal and cord immunoglobulin G levels achieved by respiratory syncytial virus vaccination were compared to those associated with maternal natural respiratory syncytial virus infection, using banked blood from 20 maternal:cord dyads collected prior to the availability of the maternal respiratory syncytial virus vaccine. Levels of immunoglobulin G against respiratory syncytial virus strain A2 and B fusion (F) and attachment (G) proteins and against pertussis toxin (as a comparator antigen from a vaccine routinely administered earlier in pregnancy) were measured using a Binding Antibody Multiplex Assay. Differences in titers between vaccination and natural infection were examined using Wilcoxon rank-sum test. Differences in cord:maternal transfer ratios and 2-month infant antibody levels by timing of maternal vaccination were evaluated by Kruskal-Wallis testing. RESULTS: Maternal respiratory syncytial virus vaccination resulted in significantly higher maternal and cord antirespiratory syncytial virus F antibody levels than natural infection (5.72 vs 4.82 log10 mean fluorescence intensity, P<.0001 maternal; 5.81 vs 5.03 log10 mean fluorescence intensity, P<.0001 cord). Maternal vaccination 2 to 3 weeks and 3 to 4 weeks prior to delivery was associated with significantly lower cord:maternal transfer ratios than were observed when vaccination occurred >5 weeks prior to delivery (P=.03 for 2-3 weeks, P=.007 for 3-4 weeks), and significantly lower transfer ratios than observed for pertussis vaccination administered prior to 30 weeks of gestation (P=.008 for 2-3 weeks, P=.03 for 3-4 weeks, similar at >4 weeks). CONCLUSION: Vaccine administration earlier in the approved 32 to 36 week window (at least 5 weeks prior to delivery) results in the highest transplacental transfer of maternal antibodies to the neonate. These results should inform the counseling of pregnant individuals on optimal vaccination timing.
引用
- Jasset OJ, Lopez Zapana PA, Bahadir Z, et al. Enhanced placental antibody transfer efficiency with longer interval between maternal respiratory syncytial virus vaccination and birth. Am J Obstet Gynecol. 2024. PMID: 39515450. doi:10.1016/j.ajog.2024.10.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。